Clinical AI governance is the set of organizational structures, policies, and oversight processes that health systems use to evaluate, approve, monitor, and retire AI tools used in clinical settings. It differs from general enterprise AI governance in scope and consequence: clinical AI tools influence diagnosis, treatment selection, medication decisions, and patient routing, which means the governance failure modes carry clinical, regulatory, and legal exposure simultaneously.
This post is a working framework for CIOs, CMIOs, and compliance teams building or maturing clinical AI governance programs. It covers how clinical AI governance differs from general AI governance, what a clinical AI committee actually does, the regulatory requirements that define the compliance baseline, and how to structure a governance program that can scale as AI adoption in your organization expands.
Why clinical AI governance is different from general AI governance
Enterprise AI governance, in most industries, focuses on a core set of concerns: model accuracy, bias in outputs, data privacy, explainability, and vendor risk. These concerns apply to clinical AI as well. But clinical AI adds dimensions that have no equivalent in a general AI governance framework.
Patient safety. A customer service chatbot that gives wrong information creates a service problem. A clinical decision support tool that gives wrong recommendations creates a patient safety event. The clinical AI governance program must include mechanisms for detecting when an AI tool is contributing to adverse outcomes, not just when it fails to perform as specified.
Regulatory classification. Not all software is created equal under federal law. The FDA regulates certain AI tools as medical devices under the Software as a Medical Device framework. The ONC HTI-1 Rule, published in January 2024, imposes transparency requirements on AI-powered clinical decision support used within certified health IT. HIPAA governs how PHI can be used in AI training data, model inference, and logging. Understanding which regulatory frameworks apply to a given AI tool is a prerequisite for governing it correctly, and the answer varies by tool type, clinical use case, and deployment context.
Physician oversight and accountability. Clinical AI tools operate in an environment where a licensed clinician bears ultimate accountability for patient care decisions. Governance must address how AI recommendations are presented to clinicians, what training clinicians receive, how disagreements between AI recommendations and clinical judgment are handled, and what documentation requirements exist when AI influences a clinical decision.
Speed of adoption vs. governance infrastructure. Clinicians and clinical departments are adopting AI tools at a pace that most health system governance programs cannot match. Shadow AI in clinical settings (AI tools procured and deployed outside IT and compliance review) is now one of the most common gaps Tristella finds in health system AI governance gap assessments. The governance program must address not just new AI procurement but existing clinical AI that was never formally reviewed.
The regulatory landscape health system AI governance must address
Health system AI governance does not exist in a regulatory vacuum. The compliance baseline for clinical AI governance draws from multiple overlapping frameworks, and the combination is what makes this harder than general enterprise AI governance.
FDA Software as a Medical Device. The 21st Century Cures Act established criteria for when AI-powered clinical decision support is exempt from FDA device classification. The exemption applies when the tool does not acquire or analyze medical images, physiological signals, or in vitro diagnostics; when it is not intended to be the sole basis for diagnosis or treatment decisions; when it supports rather than replaces clinician judgment; and when the clinician can independently review the basis for the AI's recommendation. AI tools that do not meet all four criteria may be regulated as SaMD, subject to FDA clearance or approval requirements based on their risk classification. Health systems that deploy third-party AI tools without verifying regulatory status, or that build internal AI tools without assessing SaMD applicability, are carrying regulatory exposure they may not be aware of.
ONC HTI-1 Rule. The Health Data, Technology, and Interoperability rule introduced transparency requirements for AI and ML-based predictive decision support functions used within certified EHR systems. Health systems using AI-powered CDS in their certified EHR environment need to understand how those features are documented, what transparency obligations fall on the health system versus the vendor, and how the HTI-1 requirements interact with their existing clinical governance processes.
HIPAA and clinical AI. PHI may enter AI systems through training data, through inference-time queries, and through logged outputs. Each of these represents a potential HIPAA exposure if the AI vendor is not covered by a Business Associate Agreement, if the PHI is retained beyond what the BAA permits, or if access controls are insufficient. The clinical AI governance program needs a systematic process for verifying BAA coverage for every AI tool that touches PHI, not just the ones that were obviously clinical from the start.
For a fuller treatment of how these frameworks intersect, our post on HIPAA and clinical AI compliance covers the compliance landscape in depth. The governance framework described in this post is built to operate within those constraints.
What a clinical AI committee does
A clinical AI committee (sometimes called a Clinical AI Oversight Committee, AI Governance Board, or Clinical AI Review Board) is the organizational mechanism through which health systems apply consistent governance to AI tools used in clinical settings. Its function is distinct from a general IT review board or a vendor management committee.
Composition. An effective clinical AI committee includes representation from clinical informatics, the CMIO's office, legal and compliance, risk management, nursing leadership, IT security, and at least one operational clinical department. Without clinical representation with actual decision-making authority, the committee becomes a rubber stamp. Without compliance and legal representation, governance decisions may satisfy clinical intuition but miss regulatory requirements.
Pre-deployment review. Before any AI tool goes live in a clinical setting, the committee reviews the vendor's clinical validation evidence, the FDA regulatory classification of the tool, BAA coverage, the deployment plan, and the training and change management plan for the clinical staff who will use it. The review process should be risk-tiered: a high-risk autonomous diagnostic tool requires more scrutiny than a documentation assistance AI, and the committee's process should reflect that.
Ongoing monitoring. Clinical AI tools do not perform consistently over time. Model drift, changes in the patient population, EHR configuration changes, and vendor updates can all degrade performance after deployment. The committee establishes monitoring requirements for active AI tools, reviews performance data on a defined cadence, and escalates concerns to clinical and operational leadership when monitoring reveals problems.
Incident response. When a clinical AI tool contributes to a near-miss or adverse event, or when a significant performance failure is identified, the committee leads the investigation and determines whether the tool should be suspended, modified, or decommissioned. Governance programs that lack clear incident response protocols tend to discover after the fact that no one had the authority to take a clinical AI tool offline.
Decommissioning. AI tools that are no longer performing to standard, that have been superseded by better tools, or that no longer meet regulatory requirements need a defined decommissioning process. This includes data retention decisions, vendor offboarding, and clinical staff communication.
A practical clinical AI governance framework
The most common failure mode in health system AI governance is a framework that is comprehensive on paper but not operational in practice. Governance frameworks that try to govern everything with the same level of intensity become bottlenecks that clinical departments route around. The clinical AI governance framework needs to be risk-proportionate, meaning the governance overhead applied to any given AI tool should match the clinical and regulatory risk that tool carries.
Tristella's Polaris AI Risk Management Framework defines six governance pillars that apply directly to clinical AI governance programs:
AI inventory and risk classification. You cannot govern what you cannot see. The first step in any clinical AI governance program is a complete inventory of AI tools currently in use across the health system, including tools deployed at the department level outside central IT review. Each tool is then assigned a risk tier based on clinical use case, autonomy level, FDA regulatory status, and PHI involvement. High-risk tools (autonomous diagnosis, AI-driven treatment recommendations, tools functioning as SaMD) receive the most intensive governance. Lower-risk tools (scheduling AI, documentation assistance, administrative workflow automation) receive lighter-touch oversight.
Governance accountability. The clinical AI committee charter defines who has authority to approve, suspend, or decommission clinical AI tools. The accountability map covers the vendor relationship owner, the clinical owner who is accountable for how the tool is used in practice, the compliance owner who tracks regulatory requirements, and the escalation path when the committee cannot reach agreement. Governance without defined accountability defaults to the status quo.
Data practices. Clinical AI governance must address how PHI flows into and out of AI systems, what data retention policies govern AI-related logs and outputs, how training data is managed, and how de-identification is validated when AI vendors claim their tools do not use PHI. BAA coverage is tracked centrally and reviewed as vendor contracts are renewed or amended.
Output quality and human oversight. For each AI tool in the inventory, the governance program defines the human review requirements that apply to AI outputs before they influence clinical decisions. High-risk tools require explicit physician review and documentation of that review. Lower-risk tools may have less formal review requirements, but the governance program should define what "appropriate oversight" means for each tier rather than leaving it to individual clinician discretion.
Third-party AI risk. Health systems rarely build clinical AI tools from scratch; they deploy vendor tools. The vendor risk management process for clinical AI must address more than standard vendor security review. It must also address clinical validation methodology, FDA regulatory status, what happens to PHI when the vendor relationship ends, and what the vendor's process is for managing model updates that could affect clinical performance.
Incident response. The incident response protocol for clinical AI defines how adverse events or near-misses involving AI tools are identified, escalated, investigated, and resolved. It also defines how findings from clinical AI incidents feed back into the governance program, updating risk classifications, modifying monitoring requirements, or triggering committee review of similar tools.
FDA compliance and clinical AI: what actually triggers device regulation
The question health system compliance teams ask most often about clinical AI is some version of: does this tool need FDA clearance? The answer is not always obvious and depends on how the tool is configured, how it is used, and what claims the vendor makes about it.
The four-criteria test for CDS exemption from device classification is a starting point, not a conclusion. The key factors to examine are whether the tool makes autonomous recommendations without requiring clinician review, whether it processes diagnostic inputs (images, lab values, signals) as its primary function, and whether the vendor markets it as a diagnostic or treatment decision tool. Vendors sometimes position tools to appear as CDS while functionally operating as diagnostic aids, and health systems that accept vendor claims at face value without independent review can deploy uncleared medical devices without knowing it.
The practical implication for clinical AI governance programs is that FDA regulatory status needs to be verified as part of the pre-deployment review process, not accepted from vendor documentation alone. This means reviewing the tool's 510(k) clearance or PMA approval if the vendor claims device status, and documenting the basis for a non-device determination if the vendor claims CDS exemption. The governance program should also track FDA guidance updates, because the regulatory landscape for clinical AI is evolving and tools that are currently exempt may not remain exempt as the FDA's AI/ML framework matures.
Clinical AI governance best practices
Governance programs that work in practice share a set of characteristics that distinguish them from programs that exist on paper but do not change behavior.
The committee has real authority. A clinical AI committee that can only advise but cannot block deployment or suspend active tools is not a governance structure. It is a documentation process. Effective clinical AI governance programs give the committee explicit authority to approve, conditionally approve, suspend, and decommission clinical AI tools, with an escalation path to the CMO, CNO, and board for high-stakes decisions.
Risk tiering is applied consistently. Governance overhead should be proportionate to risk. A program that applies the same intensive review to a documentation AI and an autonomous sepsis detection tool will slow down everything and get routed around. A tiered approach reserves intensive pre-deployment review for high-risk tools and applies lighter-touch review for administrative AI, which allows the governance program to function without becoming a bottleneck.
Shadow AI is addressed systematically. The governance program includes a process for identifying and reviewing AI tools that are already in use but have not gone through formal review. This is uncomfortable work because it requires finding and potentially suspending tools that clinical departments have become dependent on. It is also necessary, because the highest-risk unreviewed AI tools are usually the ones that were deployed precisely because they seemed clinically useful.
Vendors are held to defined standards. The clinical AI vendor management process includes defined requirements that vendors must meet: clinical validation documentation, FDA regulatory status documentation, BAA coverage, data retention policies, and a commitment to notify the health system of model updates that may affect performance. Vendors that cannot meet these requirements should not be in the clinical AI portfolio.
Governance evolves as AI adoption grows. A clinical AI governance program designed for five tools needs to be redesigned when the inventory reaches fifty. Build the governance infrastructure to scale, with standardized intake processes, tiered review workflows, and committee capacity that can grow without requiring a full redesign.
How health systems get started
Most health systems beginning a formal clinical AI governance program are starting from a position where AI tools are already deployed, and the governance infrastructure does not yet exist. The gap between AI adoption and AI governance is real, and it grows every quarter as AI vendors market aggressively to clinical departments.
The starting sequence that works: begin with an inventory, not a policy. Policies without an inventory govern hypothetical tools, not the ones actually running in your organization. A focused discovery effort (conversations with clinical informatics, department leads, EHR administrators, and vendor management) typically surfaces more AI tools than expected and reveals the shadow AI problem in concrete terms.
Once the inventory exists, apply the risk classification framework. This gives the committee a prioritized work list: high-risk tools that need immediate review, medium-risk tools that need formal governance over the next 90 days, and lower-risk tools that can be governed on a longer timeline.
Tristella's AI governance advisory practice works with health systems at this stage: building the governance structure, conducting the initial inventory and risk classification, and establishing the committee charter and process before the committee takes on active tool reviews. Our partners do this work directly on every engagement, which matters when the decisions being made require senior clinical and regulatory judgment.
If your organization wants to understand where its governance gaps are before building the program, our AI governance gap assessment is a structured starting point that produces a prioritized gap analysis and a roadmap for closing it.
Tristella's AI governance advisory practice covers clinical AI governance program design, AI governance gap assessments, and ongoing governance advisory for health systems and digital health organizations. Contact us to discuss where your organization is and what a governance program appropriate to your AI portfolio would look like.
Related reading: